Trials / Active Not Recruiting
Active Not RecruitingNCT04161755
Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery
Phase 1 Clinical Trial of Personalized Neoantigen Tumor Vaccines and Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Surgically Resected Pancreatic Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety or treating pancreatic cancer with surgery to remove cancerour tissue, followed by atezolizumab, followed by a personalized cancer vaccine (PCV), and then with chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atezolizumab | Atezolizumab will be administered 6 weeks post-tumor resection (+/- 2 weeks) |
| BIOLOGICAL | RO7198457 | RO7198457 will be administered 9 weeks post-tumor resection (+/- 2 weeks) |
| DRUG | mFOLFIRINOX | mFOLFIRINOX regimen will be administered 21 weeks post-tumor resection (+/- 2 weeks) |
Timeline
- Start date
- 2019-12-13
- Primary completion
- 2026-11-11
- Completion
- 2026-11-11
- First posted
- 2019-11-13
- Last updated
- 2026-01-07
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04161755. Inclusion in this directory is not an endorsement.